三重激动剂 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Ropinirole is metabolized primarily by cytochrome P450 CYP1A2 to form two metabolites; SK&F-104557 (N-Despropyl Ropinirole) and SK&F-89124, both of which are renally excreted, and at doses higher than clinical, is also metabolized by CYP3A4. At doses greater than 24 mg, CYP2D6 may be inhibited, although this has been tested only in vitro. 7-Hydroxyropinirole (SK&F-89124), a major metabolite of ropinirole in rats but minor metabolite in humans (<5% of dose), is a highly potent dopamine receptor agonist with antiparkinsonian activity similarly to ropinirole. It has been reported to be 30-fold more potent than ropinirole as a dopamine D2 receptor agonist in vitro. However, ropinirole and 7-hydroxyropinirole were equipotent in terms of antiparkinsonian activity in rodents in vivo. 7-Hydroxyropinirole is said to be the only metabolite of ropinirole known to possess significant dopaminergic activity in vivo, although other ropinirole metabolites have also been found to have dopaminergic activity.
the first technological developments were a thinner-gauge device-shell, and a filler gel of low-cohesion silicone, which improved the functionality and the verisimilitude (size, appearance, and texture) of the silicone-gel breast implant. Yet, in clinical practice, second-generation breast implants proved fragile and saw greater instances of shell rupture, and of filler leakage ("silicone-gel bleed") through the intact device shell. The consequent, increased incidence-rates of medical complications (e.g. capsular contracture) precipitated faulty-product, class action-lawsuits, by the U.S. government, against the Dow Corning Corporation, and other manufacturers of breast prostheses. the second technological development was a polyurethane foam coating for the shell of the breast implant; the coating reduced the incidence of capsular contracture, by causing an inflammatory reaction that impeded the formation of a capsule of fibrous collagen tissue around the breast implant. Nevertheless, despite that prophylactic measure, the medical use of polyurethane-coated breast implants was briefly discontinued, because of the potential health-risk posed by 2,4-toluenediamine (TDA), a carcinogenic by-product of the chemical breakdown of the polyurethane foam coating of the breast implant proven to cause liver and skin cancers in animal-model studies. After reviewing the medical data, the U.S.
UV-Vis spectrophotometer: Measures light absorption in UV and visible ranges (200-800 nm). Used for quantification of many inorganic and organic compounds. Infrared spectrophotometer: Measures infrared light absorption, allowing identification of chemical bonds and functional groups. Atomic absorption spectrophotometer (AAS): Uses absorption of light by vaporized analyte atoms to determine concentrations of metals and metalloids. Fluorescence spectrophotometer: Measures intensity of fluorescent light emitted from samples after excitation. Allows highly sensitive analysis of samples with native or induced fluorescence. Colorimeter: Simple spectrophotometers used to measure light absorption for colorimetric assays and tests.
== Detection == Separation by capillary electrophoresis can be detected by several detection devices. The majority of commercial systems use UV or UV-Vis absorbance as their primary mode of detection. In these systems, a section of the capillary itself is used as the detection cell. The use of on-tube detection enables detection of separated analytes with no loss of resolution. In general, capillaries used in capillary electrophoresis are coated with a polymer (frequently polyimide or Teflon) for increased flexibility. The portion of the capillary used for UV detection, however, must be optically transparent. For polyimide-coated capillaries, a segment of the coating is typically burned or scraped off to provide a bare window several millimeters long. This bare section of capillary can break easily, and capillaries with transparent coatings are available to increase the stability of the cell window. The path length of the detection cell in capillary electrophoresis (~ 50 micrometers) is far less than that of a traditional UV cell (~ 1 cm). According to the Beer-Lambert law, the sensitivity of the detector is proportional to the path length of the cell. To improve the sensitivity, the path length can be increased, though this results in a loss of resolution. The capillary tube itself can be expanded at the detection point, creating a "bubble cell" with a longer path length or additional tubing can be added at the detection point as shown in figure 2. Both of these methods, however, will decrease the resolution of the separation.
==== Clay ==== The clay hypothesis was proposed by Graham Cairns-Smith in 1985. It postulates that complex organic molecules arose gradually on pre-existing, non-organic replication surfaces of silicate crystals in contact with an aqueous solution. The clay mineral montmorillonite has been shown to catalyze the polymerization of RNA in aqueous solution from nucleotide monomers, and the formation of membranes from lipids. In 1998, Hyman Hartman proposed that "the first organisms were self-replicating iron-rich clays which fixed carbon dioxide into oxalic acid and other dicarboxylic acids. This system of replicating clays and their metabolic phenotype then evolved into the sulfide rich region of the hot spring acquiring the ability to fix nitrogen. Finally phosphate was incorporated into the evolving system which allowed the synthesis of nucleotides and phospholipids."
Sources: en.wikipedia.org
=== Gavi Foundation === On March 24, 2025, the Department of Government Efficiency (DOGE) announced the termination of a $2.63 billion grant from USAID to the Gavi Foundation because the Gavi Foundation "prioritizes 'zero-dose' children who have not received a single vaccine shot as well as missed communities. The zero-dose agenda is also a key priority for the global community’s immunization agenda 2030, which was endorsed by the World Health Assembly in May 2020." DOGE stated the United States federal government saved $1.75 billion by cancelling the grant, which was 6.575% of the total USAID budget.
The active site is located in a long cleft running parallel with the 3 strand across the lower part of the transpeptidase domain. When carbenicillin binds to penicillin binding protein 3, it forms an acyl-enzyme complex which means the β-lactam is chemically attached to PBP3. The β-lactams are covalently bound to S294 which inactivates the enzyme. Also, the N-terminal end of PBP3 is more flexible, however, the C-terminal part, which contains the enzyme’s active site, is very stable and does not change much. The binding of carbenicillin to the active site increases the enzyme's thermostability with conformational changes. The first carboxylate group in carbenicillin forms hydrogen bonding interactions with S485, T487, and N351. These hydrogen bonding interactions help stabilize the binding between carbenicillin and PBP 3.
== Use as an educational tool == The AIDA software comes with forty educational case scenarios as standard, each of which represents a 'snapshot' of the metabolic status of a typical person with respect to insulin-dependent type 1 diabetes mellitus. It is easy for users to add or create further case scenarios, as required. Examples of the application of AIDA as an educational tool can be found in various published journal articles.
Merle Sheffield, The Chain and Boom, Hudson River Valley, official website West Point Fortifications The Great Chain Chaining of the Hudson in 1778 Archived February 16, 2008, at the Wayback Machine The Great Chain Chaining The Hudson George Washington's letter about the strategic importance of the Hudson Contract for the forging of The Great Chain New York Times Article about The Chain February 17, 1895 Chain Salvaging Blurb "Revolutionary West Point: 'The Key to the Continent'",
Sources: en.wikipedia.org
=== Modern attempts at Carbon 14 dating === Various attempts at radio-carbon analysis were made over the years, with various degrees of success, but with the main effect of pushing back the dates of the first caves to circa 300 CE, and challenging the German classification according to styles and colors schemes. In 1979, a Chinese institute (文物保护科学技术研究所, Wenwu baohu kexue jishu yanjiusuo) carbon-tested caves 63, 47, 13.
In May 2014, the Avengers S.T.A.T.I.O.N. (Scientific Training and Tactical Intelligence Operative Network) exhibit opened at the Discovery Times Square center. The exhibit features replica set pieces and props from the films, mixed with interactive technology and information, crafted through a partnership with NASA and other scientists. Titus Welliver also provides a "debrief" to visitors, reprising his role as S.H.I.E.L.D. agent Felix Blake. Created by Victory Hill Exhibits, Avengers S.T.A.T.I.O.N. cost $7.5 million to create, and ran through early September 2015. The exhibit also opened in South Korea at the War Memorial of Korea in April 2015, in Paris, France, at Esplanade de La Défense a year later, and in Las Vegas at the Treasure Island Hotel and Casino in June 2016. The Las Vegas version of the exhibit featured updated character details and corresponding science to incorporate the Marvel films that were released since the original exhibit in New York. Additionally, the Las Vegas version features Cobie Smulders reprising her role as Maria Hill to "debrief" visitors, replacing Welliver.
=== Discovery === In 1938, Emilio Segrè and Glenn T. Seaborg isolated for the first time the metastable isotope technetium-99m, after bombarding natural molybdenum with 8 MeV deuterons in the 37-inch (940 mm) cyclotron of Ernest Orlando Lawrence's Radiation laboratory. In 1970 Seaborg explained that:
1921 Research on the role of pancreas in the nutritive assimilation 1922 Frederick Banting, Charles Best and James Collip use bovine insulin extract in humans at Connaught Laboratories in Toronto, Canada. 1922 Leonard Thompson becomes the first human to be treated with insulin. 1922 James D. Havens, son of former congressman James S. Havens, becomes the first American to be treated with insulin. 1922 Elizabeth Hughes Gossett, daughter of the US Secretary of State, becomes the first American to be (officially) treated in Toronto. 1923 Dr. Trent Champion de Crespigny delivers the first treatments with insulin produced in Australia, to a 9-year-old, in Adelaide, South Australia, on 7 January 1923. 1923 Eli Lilly produces commercial quantities of much purer bovine insulin than Banting et al. had used 1923 Farbwerke Hoechst, one of the forerunners of today's Sanofi Aventis, produces commercial quantities of bovine insulin in Germany 1923 Hans Christian Hagedorn founds the Nordisk Insulinlaboratorium in Denmark – forerunner of today's Novo Nordisk 1923 Constance Collier returns to health after being successfully treated with insulin in Strasbourg 1924 Margaret Cheadle, a research biochemist in the laboratory of T. Brailsford Robertson at the University of Adelaide, determined that approx. 167 "mouse units" of insulin were "equivalent to one two-kilogram rabbit-unit". 1926 Nordisk receives a Danish charter to produce insulin as a non-profit 1936 Canadians David M. Scott and Albert M.
=== Aftermath of the conflict === According to the cable sent from Astana, Chinese Ambassador Cheng Guoping told American Ambassador to Kazakhstan in June 2009 that he expected Russia to use military force to depose Saakashvili. US Ambassador to Russia John Beyrle advised the US government in June 2009 against military cooperation with Georgia since it would harm "re-start relations with Russia", while US Ambassador to Georgia supported maintaining ties with Georgia. The cables reported that Assistant Secretary of State Philip H. Gordon was told by the French diplomatic adviser Jean-David Levitte in September 2009 that "it may take a generation before the Russian public will be able to accept their loss of influence, from Poland and the Baltics to Ukraine and Georgia. Unfortunately, the Russian tendency is to view « good neighbors » as totally submissive subordinates." Gordon said that "the U.S. pursues a policy to support Georgia in the face of Russian pressure without encouraging President Saakashvili to act in ways that are unhelpful." In September 2009, United States Assistant Secretary of Defense Alexander Vershbow told Russian Deputy Foreign Minister Grigory Karasin that the US non-lethal military aid to Georgia was "a matter of principle" and the US did "not accept any arms embargo".
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.